SecProbe.io

February 27, 2013

Via E -Mail
Jeffrey Bacha
Chief Executive Officer and President
DelMar Pharmaceuticals, Inc.
Suite 720 -999 West Broadway
Vancouver, BC
Canada V5Z 1K5

Re: DelMar  Pharmaceuticals, Inc.
 Form 8-K
Filed January 31, 2013
File No. 000 -54801

Dear Mr. Bacha :

We have reviewed your filing an d have the following comments.  In some of our
comments, we may ask you to provide us with information so we may better understand your
disclosure.

Please respond to this letter within ten business days by amending your filing, by
providing the requested information, or by advising us when you will provide the requested
response.   If you do not believe our comments apply to your fact s and circumstances or do not
believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your filing and the information you provide in
response to these  comments, we may have  additional comments.

General

1. We note your pending confidential treatment request and advise you that we will not be
in a position to conclude our review of your filing until all comments on your
confidential treatment request have been resolved.  We will deliver any comments to your
confidential treatment request under separate cover.

 “We are dependent on obtaining certain patents…” page 6

2. We note that you conduct a considerable amount of work with Guangxi Wuzhou in
China.  Please expand this risk factor and rela ted discussions, as appropriate, to disclose
that China is one of the countries that has provided less protection to a company’s
intellectual property than the United States.

Jeffrey Bacha
DelMar Pharmaceuticals, Inc.
February 27, 2013
Page 2

 VAL -083 Clinical Development in GBM, page 15

3. We note the data presented on pag e 15.  Please confirm that you have presented the data
for all patients currently enrolled.  Alternatively, please provide us with a detailed
analysis which supports your belief that the data is representative of all patients enrolled.
In addition, pleas e expand your disclosure to disclose the number of patients that you are
seeking to enroll.

Developing Partnerships with Pharmaceutical Companies
Guangxi Wuzhou Pharmaceutical Company, page 24

4. Please expand your disclosure to describe the material terms of your collaboration
agreement with Guangxi Wuzhou, including the duration and termination provisions, the
aggregate payments to date, material obligations, and the nature and scope of any
intellectual property licensed or otherwise transferred.

Item 4.  Security Ownership of Certain Beneficial Owners and Management, page 33

5. Please list Valent and RL Vollantine Construction Inc. in the table as holders of five
percent or more of your common s tock.

Item 5.  Directors and Executive Officers, page 34

6. We note your disclosure on page 22 that your executive officers are not full -time
employees, but are engaged on an independent contractor or contract -employment basis.
Please disclose the amount o f time each executive officer devotes to the company’s
business and expand your discussion on page 36 to describe any provisions of their
consulting agreements under which they allocate their time to the company.  In addition,
please file the consulting ag reements with your executive officers as exhibits pursuant to
Item 601(b)(10) of Regulation S -K.

Item 6.  Executive Compensation, page 36

7. On page F -43, you disclose that in 2012 you approved a stock option plan and granted
1,020,000 stock options under t he plan.  Please confirm that none of your executive
officers or directors received any stock options during 2012.  Alternatively, please revise
your disclosure on pages 36 and 37 to disclose the required information pursuant to Item
402 of Regulation S -K for 2012.

Item 7. Certain Relationships and Related Transactions, page 37

8. Please expand your discussion of the patent assignment agreement with Valent, as
amended, to include the duration and termination provisions and the amount of royalties

Jeffrey Bacha
DelMar Pharmaceuticals, Inc.
February 27, 2013
Page 3

 payable expressed as a percentage or range within 10% (i.e. single digits, teens, twenties,
etc.).

9. Please file copies of the following agreements with Valent pursuant to Item
601(b)(10)(ii)(A) of Regulation S -K:

 Loan agreement; and

 Agreement to access your facil ities in California, as disclosed on page 33.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure
in the filing to be certain that the filing includes the information the Securities Exchange Act of
1934 and all applicable Exchange Act rules require.   Since the company and its management are
in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy
and adequacy of t he disclosures they have made.

 In responding to our comments, please provide  a written statement from the company
acknowledging that:

 the company is responsible for the adequacy and accuracy of the disclosure in the filing;

 staff comments or changes to disclosure in response to staff comments do not foreclose
the Commission from taking any action with respect to the filing; and

 the company may not assert staff comments as a defense in any proceeding initiated by
the Commission or any person under the  federal securities laws of the United States.

Please contact Amy Reischauer at (202) 551 -3793, Jennifer Riegel at (202) 551 -3575, or
me at (202) 551 -3715 with any other questions.

Sincerely,

 /s/ Jennifer Riegel for

Jeffery P. Riedler
Assistant Director
cc: Via E -Mail
Jeff Cahlon
Sichenzia Ross Friedman Ference LLP
61 Broadway
New York, NY 10006